 |
MARKETS |
 BTA.AX | BTA(AU) ISIN:AU000000BTA1 | Australian Stock Exchange |
 | | BZK.BE | BZK(GR) | Berlin Stock Exchange |
| | BZK.F | BZK(GR) | Frankfurt Stock Exchange |
| | BZK.MU | BZK(GR) | Munich Stock Exchange |
| | BZK.DE | BZK(GR) | Xetra |
| | BTAHY.OB | BTAHY(US) | NASDAQ Dealers - Bulletin Board |
| | BTAHY.PK | BTAHY(US) | Pink Sheets (National Quotation Bureau) |
|
|
|
Biota Holdings Limited Company Summary |
 Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza.
Biota research breakthroughs have included a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease, licensed to AstraZeneca and novel nucleoside analogues designed to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems. In addition, Biota has a key partnership with Daiichi-Sankyo for the development of second generation influenza antivirals.
Relenza(TM) is a registered trademark of the GlaxoSmithKline group of companies. *Further information available at http://www.biota.com.au
|
|
|
COMPANY DATA |
 |
Headquarters |
Unit 10, 585 Blackburn Road |
|
| |
|
NOTTING HILL VIC 3168 |
|
| |
|
Australia |
|
|
Telephone |
+61 3 9915 3700 |
|
|
Fax |
+61 3 9915 3702 |
|
|
Principal Sector |
Health & Pharm |
|
|
Principal Industry |
Biotechnology |
|
|
Listed |
1985/12/20 |
|
|
Homepage |
www.biota.com.au |
|
| |
|
Options |
Click Here To Request Research Report: |
|
|
|
5,088 COMPANY PROFILE VIEWS |
|
This Page Viewed: (Last 7 Days: 23) (Last 30 Days: 96) (Since Published: 642)
|
|
|
|
|
|
|
|
NEWS  |
 |
Australian Market Report of August 13: US Economy Stabilizing
AUG 13, 2009 11:15 - Article Views: 4,506
US stocks surged overnight as the Federal Reserve said the economy was leveling out, and it left interest rates unchanged at the end of its two-day policy meeting. |
|
 |
iSOFT Group Limited (ASX:ISF) Appoints Dr. James Fox As Non-Executive Director
JULY 8, 2009 09:57 - Article Views: 2,393
iSOFT Group Limited (ASX:ISF) Australia's largest listed health information technology company today announced the appointment of Dr. James (Jim) Fox as Non-Executive Director, as iSOFT seeks to increase the number of independent directors on its Board. |
|
 |
Biota Holdings Limited (ASX:BTA) Notes Important Initiatives By GSK to Respond to the New Influenza A (H1N1) Strain
MAY 4, 2009 09:25 - Article Views: 1,953
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) notes that GlaxoSmithKline (GSK) has announced important initiatives to assist governments and health authorities around the world to respond to the emergence of the new influenza A (H1N1) strain (previously referred to as Swine Flu). |
|
 |
Biota Holdings Limited (ASX:BTA) Announced Thier Relenza Royalty for March 2009 Quarter At A$32.3 Million
APR 23, 2009 10:52 - Article Views: 2,404
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that it had received notification from GlaxoSmithKline (LON:GSK) that Relenza sales were A$462 million and indicative royalties were A$32.3 million, for the three months ended 31 March 2009. |
|
 |
Australian Market Report of March 30: A Slowdown after Weeks of Rallies
MAR 30, 2009 13:00 - Article Views: 3,905
The Australian share closed slightly higher lifted by miners. The benchmark S&P/ASX200 index ended the day up 0.7%, or 25.7 points, at 3672.3, while the broader All Ordinaries index rose 0.8%, or 29.3 points, at 3615.6. For the week, the ASX200 added 6% and the All Ordinaries rose 6.2%. |
|
 |
Biota Holdings Limited (ASX:BTA) Daiichi-Sankyo (TYO:4568) Exercise Right To Market CS-8958 In Japan
MAR 30, 2009 09:41 - Article Views: 1,794
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that Daiichi Sankyo (TYO:4568), the co-owner of the long acting neuraminidase inhibitor (LANI) CS-8958, has signed a contract to manufacture and market the product in Japan, pending the successful completion of the pivotal Phase III clinical studies and on obtaining registration approval. Biota, as one of the owners, will receive an undisclosed royalty on sales and a number of fixed sum payments on the achievement of certain sales milestones in the Japanese market. |
|
 |
Biota Holdings Limited (ASX:BTA) Announces The Appointment Of Dr James Fox As Non Executive Director And Chairman
MAR 2, 2009 09:58 - Article Views: 937
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) announced today the appointment of Dr James Fox as a non executive Director and Chairman, effective 27 February 2008. |
|
|
Biota Holdings Limited (ASX:BTA) Interview With CEO Peter Cook
FEB 18, 2009 11:58 - Article Views: 1,351
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today reported NPAT of A$7.2 million for the first half ended December 2008, up 31 percent from the previous corresponding period. Excluding the A$20 million GlaxoSmithKline (GSK) litigation settlement, the underlying business booked a net loss of A$12.8 million for the half versus net profit of A$5.5 million previously. |
|
|
Biota Holdings Limited (ASX: BTA) Today Announces A Half Year Net Profit After Tax Of A$7.2 Million An Increase Of 31%
FEB 18, 2009 09:33 - Article Views: 768
Biota Holdings Limited (ASX: BTA)(PINK:BTAHY) today announced a half year net profit after tax of A$7.2 million, (1H F08: A$5.5 million), a 31% improvement over first half F08. Profit before tax was A$10.1 million (1H F08: A$7.5 million) and includes A$12.7 million from the GSK litigation settlement in the period. |
|
|
Biota Holdings Limited (ASX:BTA) Revised Relenza Royalty For December 2008 Quarter
FEB 13, 2009 11:45 - Article Views: 1,301
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today reported that it had received revised advice from GlaxoSmithKline (GSK) regarding Relenza sales for the December 2008 quarter. The revised sales were A$27.1 million (US$20.8 million) and indicative royalties were A$1.9 million (US$1.46 million). |
|
|
|
|
More Articles:
|
|
